Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487490 | 0.88 | HDAC1 (0.37) | HDAC1HDAC8 | |
| SCHEMBL2541221 | 0.88 | HDAC1 (0.37) | HDAC1HDAC8 | |
| SCHEMBL8203154 | 0.88 | HDAC1 (0.37) | HDAC1HDAC8 | |
| SCHEMBL7859864 | 0.87 | HDAC1 (0.35) | HDAC1HDAC8 | |
| SCHEMBL1490123 | 0.86 | HDAC1 (0.36) | HDAC1HDAC8 | |
| SCHEMBL1490122 | 0.86 | HDAC1 (0.36) | HDAC1HDAC8 | |
| SCHEMBL1490120 | 0.86 | HDAC1 (0.36) | HDAC1HDAC8 | |
| SCHEMBL1487534 | 0.85 | CYP3A4 (0.35) | — | |
| SCHEMBL2537964 | 0.85 | CYP3A4 (0.35) | — | |
| SCHEMBL1937243 | 0.85 | HDAC1 (0.36) | HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044023-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090297472-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297472-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | HDAC1 1626/4885HDAC8 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.